Dec 2 news release "Apabetalone treatment improves cognition in CVD patients with diabetes....."The effects seen in the BETonMACE trial for those with cognitive impairment are very promising and suggest that epigenetic modulators such as apabetalone may represent an important and novel approach to treatment of cognitive disorders,” stated Dr. Jeff Cummings, Vice Chair of Lou Ruvo Brain Health Center, Las Vegas, and one of the presenters during the CtAD Symposium."
Clear to me from Dec 2 news release that they were talking about cognition endpoint(s). But they did not use statistically significant here.
Dec 5 news release: "the Company will hold a conference call and webcast on December 6th at 8:30 am ET to supplement the presentation of prespecified BETonMACE cognition results to be disclosed at the Clinical Trials on Alzheimer's Disease (“CtAD”) Congress 2019. Among other findings, the Company will highlight that Apabetalone treatment illustrated statistically significant improvements compared to top standard of care placebo in cardiovascular disease patients with moderate to severe cognitive decline."
Not clear to me from Dec 5 news release that the statistically significant improvements refer to MoCA scores or other cognition endpoint. If you take a look at the cognition sub-study posters and presentation, you will appreciate that there are other clinical chemistry measures that this statistically significant improvement may be referring to. It could even be referring to MACE reduction or eGFR improvement within the cognition sub-group. In the context of the Dec 2 news release, it is implied that it was the cognition improvements that were statistically significant. However, I agree there is enough ambiguity in the language to create uncertainty. Tick tock. 12 hours to go.
https://www.resverlogix.com/upload/event/42/4388386bbd26/2019-03-29---ad-pd-2019-cummings-final.pdf
https://www.resverlogix.com/upload/media_element/173/b9738b92dd21/2019-07-08---aaic-poster-2019-final.pdf
https://www.resverlogix.com/upload/media_element/162/8d742e28b23b/2019-acc-poster-bet-protein-inhibition.pdf
